Grimes & Company, Inc. Biogen Inc. Transaction History

Grimes & Company, Inc.

$3.18 Billion
Q1 2025

A detailed history of Grimes & Company, Inc. transactions in Biogen Inc. stock. As of the latest transaction made, Grimes & Company, Inc. holds 59,334 shares of BIIB stock, worth $6.91 Million. This represents 0.26% of its overall portfolio holdings.

Number of Shares

59,334

Previous 25,613 131.66%

Holding current value

$6.91 Million

Previous $3.92 Million 107.33%

% of portfolio

0.26%

Previous 0.11%

30 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q1 2025 Apr 17, 2025	BUY	$133.43 - $153.27 $4.5 Million - $5.17 Million	33,721 Added 131.66%	59,334 $8.12 Million
Q4 2024 Jan 21, 2025	SELL	$146.47 - $191.55 $3.2 Million - $4.19 Million	-21,854 Reduced 46.04%	25,613 $3.92 Million
Q3 2024 Oct 22, 2024	SELL	$189.07 - $236.8 $51,616 - $64,646	-273 Reduced 0.57%	47,467 $9.2 Million
Q2 2024 Jul 22, 2024	BUY	$190.52 - $236.72 $162,323 - $201,685	852 Added 1.82%	47,740 $11.1 Million
Q1 2024 Apr 17, 2024	BUY	$212.02 - $267.71 $358,101 - $452,162	1,689 Added 3.74%	46,888 $10.1 Million
Q4 2023 Jan 24, 2024	BUY	$222.59 - $267.94 $140,009 - $168,534	629 Added 1.41%	45,199 $11.7 Million
Q3 2023 Oct 19, 2023	BUY	$253.3 - $285.89 $123,103 - $138,942	486 Added 1.1%	44,570 $11.5 Million
Q2 2023 Jul 19, 2023	SELL	$275.25 - $318.06 $111,201 - $128,496	-404 Reduced 0.91%	44,084 $12.6 Million
Q1 2023 Apr 20, 2023	SELL	$256.56 - $292.34 $396,898 - $452,249	-1,547 Reduced 3.36%	44,488 $12.4 Million
Q4 2022 Jan 25, 2023	SELL	$252.44 - $306.72 $173,173 - $210,409	-686 Reduced 1.47%	46,035 $0
Q3 2022 Oct 28, 2022	BUY	$194.69 - $268.46 $115,840 - $159,733	595 Added 1.29%	46,721 $12.5 Million
Q2 2022 Jul 22, 2022	BUY	$187.54 - $223.02 $175,912 - $209,192	938 Added 2.08%	46,126 $9.41 Million
Q1 2022 May 06, 2022	BUY	$193.77 - $244.14 $709,004 - $893,308	3,659 Added 8.81%	45,188 $9.52 Million
Q4 2021 Feb 01, 2022	SELL	$223.92 - $287.77 $69,863 - $89,784	-312 Reduced 0.75%	41,529 $9.96 Million
Q3 2021 Nov 08, 2021	SELL	$282.99 - $369.05 $3,678 - $4,797	-13 Reduced 0.03%	41,841 $11.8 Million
Q2 2021 Aug 04, 2021	SELL	$259.0 - $414.71 $51,023 - $81,697	-197 Reduced 0.47%	41,854 $14.5 Million
Q1 2021 May 12, 2021	BUY	$242.95 - $284.63 $811,695 - $950,948	3,341 Added 8.63%	42,051 $11.8 Million
Q4 2020 Feb 02, 2021	BUY	$236.26 - $355.63 $711,142 - $1.07 Million	3,010 Added 8.43%	38,710 $9.48 Million
Q3 2020 Nov 12, 2020	BUY	$264.77 - $305.71 $928,283 - $1.07 Million	3,506 Added 10.89%	35,700 $10.1 Million
Q2 2020 Jul 31, 2020	SELL	$258.66 - $342.55 $50,438 - $66,797	-195 Reduced 0.6%	32,194 $8.61 Million
Q1 2020 May 05, 2020	SELL	$268.85 - $341.04 $88,182 - $111,861	-328 Reduced 1.0%	32,389 $10.2 Million
Q4 2019 Feb 05, 2020	SELL	$220.06 - $304.07 $1.15 Million - $1.59 Million	-5,239 Reduced 13.8%	32,717 $9.71 Million
Q3 2019 Nov 05, 2019	BUY	$217.44 - $243.88 $7.87 Million - $8.83 Million	36,196 Added 2056.59%	37,956 $8.84 Million
Q2 2019 Jul 30, 2019	SELL	$219.29 - $241.72 $219,290 - $241,720	-1,000 Reduced 36.23%	1,760 $412,000
Q1 2019 May 02, 2019	BUY	$216.71 - $338.96 $216,710 - $338,960	1,000 Added 56.82%	2,760 $653,000
Q4 2018 Feb 01, 2019	SELL	$278.5 - $352.75 $81,322 - $103,003	-292 Reduced 14.23%	1,760 $530,000
Q3 2018 Nov 09, 2018	BUY	$293.51 - $383.83 $27,002 - $35,312	92 Added 4.69%	2,052 $725,000
Q2 2018 Aug 10, 2018	BUY	$257.52 - $306.91 $162,237 - $193,353	630 Added 47.37%	1,960 $569,000
Q1 2018 May 07, 2018	SELL	$260.13 - $367.91 $9,104 - $12,876	-35 Reduced 2.56%	1,330 $364,000
Q3 2017 Nov 03, 2017	BUY	$281.15 - $329.69 $383,769 - $450,026	1,365	1,365 $427,000

Others Institutions Holding BIIB

# of Institutions

1,016

Shares Held

127M

Call Options Held

1.77M

Put Options Held

2.34M

View Full List

About BIOGEN INC.

Ticker BIIB
Exchange NASDAQ
Sector Healthcare
Industry Drug Manufacturers—General
Shares Outstandng 144,000,992
Market Cap $16.8B
Description
Biogen Inc. discovers, develops, manufactures, and delivers therapies for treating neurological and neurodegenerative diseases. The company offers TECFIDERA, VUMERITY, AVONEX, PLEGRIDY, TYSABRI, and FAMPYRA for multiple sclerosis (MS); SPINRAZA for spinal muscular atrophy; and FUMADERM to treat plaque psoriasis. It also provides BENEPALI, an eta...

More about BIIB

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Grimes & Company, Inc., based on Form 13F filings with the SEC.

News

Stay updated on Grimes & Company, Inc. with notifications on news.

Account

Grimes & Company, Inc. Biogen Inc. Transaction History